Ionis Pharmaceuti…
USUSDIonis Pharmaceuticals Inc (US:IONS) — Biotechnology: Pharmaceutical Preparations. Количество бирж, на которых торгуются акции компании: 3. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- ionis.com
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Штаб-квартира
- CARLSBAD, United States
- Генеральный директор
- Dr. Brett P. Monia Ph.D.
- Сотрудники
- 1 480
- Акций в обращении
- Свободное обращение
- 164.82 млн
- Рыночная капитализация
- 7.42 млрд USD
- Инсайдеры
- 0.61%
- Институциональные инвесторы
- 110.5%
- Отрасль (SIC)
- Pharmaceutical Preparations
- ISIN
- US4622221004
- LEI
- 549300SI4ZGLG0BLUZ92
Описание
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Дивиденды
Выплаты дивидендов не обнаружены (проверено 09.10.2026). Компания, вероятно, не выплачивает дивиденды.
Новости этой недели
Новостей с сайта компании пока нет.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| FMR, LLC | 14.82% | 24.63 млн | 2026-06-30 |
| Capital World Investors | 13.04% | 21.67 млн | 2026-06-30 |
| Blackrock Inc. | 6.44% | 10.7 млн | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 5.12% | 8.5 млн | 2026-07-31 |
| Vanguard Portfolio Manag… | 4.73% | 7.86 млн | 2026-06-30 |
| Growth Fund of America | 4.61% | 7.67 млн | 2026-06-30 |
| Wellington Management Gr… | 4.6% | 7.65 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.34% | 7.21 млн | 2026-06-30 |
| Two Sigma Investments, L… | 3.76% | 6.25 млн | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 3.74% | 6.21 млн | 2026-07-31 |
| Royal Bank of Canada | 3.72% | 6.18 млн | 2026-06-30 |
| SmallCap World Fund Inc | 3.17% | 5.26 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3% | 4.99 млн | 2026-06-30 |
| New Economy Fund | 2.93% | 4.87 млн | 2026-06-30 |
| State Street Corporation | 2.61% | 4.33 млн | 2026-06-30 |
| T. Rowe Price Investment… | 2.38% | 3.96 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 3.6 млн | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.44% | 2.39 млн | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.25% | 2.08 млн | 2026-06-30 |
| T. Rowe Price Mid-Cap Gr… | 1.2% | 2 млн | 2026-06-30 |
| MONIA BRETT P (Chief Exe… | ≈0.15% | 245 571 | 2026-06-26 |
| BERTHELSEN SPENCER R (Di… | ≈0.1% | 161 303 | 2026-07-15 |
| HOUGEN ELIZABETH L (Chie… | ≈0.05% | 82 660 | 2026-03-17 |
| SCHNEIDER EUGENE (Office… | ≈0.05% | 77 114 | 2026-06-26 |
| BIRCHLER BRIAN (Officer) | ≈0.04% | 67 500 | 2026-04-16 |
| O'NEIL PATRICK R (Genera… | ≈0.04% | 61 470 | 2026-06-26 |
| GEARY RICHARD S (Officer… | ≈0.04% | 59 657 | 2025-11-06 |
| BAROLDI JOSEPH (Officer) | — | — | 2026-06-26 |
| BENNETT C FRANK (Officer… | — | — | 2026-07-07 |
| HAYDEN MICHAEL REUBEN (D… | — | — | 2026-07-31 |
